| Autor: |
Fatobene, Giancarlo, Linardi, Camila da Cruz Gouveia, Moreira, Frederico, Targueta, Gabriela Matos Falcão, Santos, Fernanda Maria, Velasques, Rodrigo Dolphini, Rocha, Vanderson, Buccheri, Valeria |
| Předmět: |
|
| Zdroj: |
Hematological Oncology; Aug2019, Vol. 37 Issue 3, p310-313, 4p |
| Abstrakt: |
Highlights from the article: Classical Hodgkin lymphoma (CHL) accounts for approximately 10% of all lymphomas, and about 20% of patients experience relapse or primary refractory disease. In this group, autologous stem cell transplantation (ASCT) has become the standard of care.[[1]] Several groups have pointed out prognostic factors among these high-risk patients.[[3]] To our knowledge, there is no large cohort of relapsed and refractory CHL patients in Latin America. Refractory patients were defined as obtaining less than a complete remission (CR) or partial remission (PR) at the end of first-line chemotherapy, and relapsed patients were those who relapsed after achieving a CR for at least 3 months. 3 Patients not immediately referred to ASCT at progression/relapse due to patient initial refusal or because frontline ASCT was not the standard therapy at our institution in the 1990's. |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text